NCT03114631

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

Single-center Trial Evaluating the Safety and Efficacy of MUC-1/WT-1 Peptide or Tumor Lysate-pulsed Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: The Republican Research and Practical Center for Epidemiology and Microbiology · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The trial evaluates the safety and efficacy of MUC-1/WT-1 peptide and/or tumor lysate-pulsed dendritic cell Immunotherapy for the patients with pancreatic cancer

Detailed description

The trial evaluates the safety and efficacy of dendritic cell Immunotherapy for the patients with pancreatic cancer. Dendritic cells are obtained from blood monocytes using standard protocol. Two options for dendritic cell priming are used: MUC-1/WT-1 peptides for the patients with unresectable tumor and/or tumor lysates for the patients undergoing tumor resection. The dendritic cells are them matured and injected subcutaneous (all patients) and intratumorally (when possible).

Conditions

• Dendritic Cells
• Pancreatic Neoplasms

Interventions

Type	Name	Description
BIOLOGICAL	Dendritic cells pulsed with tumor lysate
BIOLOGICAL	Dendritic cells pulsed with MUC-1/WT-1 peptides

Timeline

• Start date: 2017-01-09
• Primary completion: 2019-05-03
• Completion: 2019-05-23
• First posted: 2017-04-14
• Last updated: 2019-12-03

Locations

1 site across 1 country: Belarus